Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Roivant Sciences (ROIV – Research Report). The company’s ...

Immunovant (Nasdaq: IMVT), a Roivant Sciences company, today reported top-line results from its Phase III study of batoclimab ...

With $75.1 million in cash and minimal competition, aTyr Pharma is well-positioned financially, making it a compelling ...

In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...

In its fourth quarter 2024 investor letter, Tourlite Capital Management emphasized stocks such as Roivant Sciences Ltd. (NASDAQ:ROIV). Roivant Sciences Ltd. (NASDAQ:ROIV) is a commercial-stage ...

Roivant Sciences stock opened at $10.60 on Tuesday. The stock’s 50 day moving average price is $10.99 and its 200 day moving average price is $11.56. The firm has a market capitalization of $7. ...

It’s the latest development in a bitter patent feud in which Arbutus and Genevant, a joint venture between Arbutus and Roivant that holds ... respond to Fierce Pharma’s request for comment.

Roivant Sciences (Nasdaq: ROIV ... Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. Updates from clinical trials, conferences, M&A, licensing, financing, ...

In this article, we are going to take a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) stands against the other cash-rich mid cap stocks. Cash flow is the money moving in and out of a business ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on developing and bringing medicines to market, especially for inflammation and immune-related diseases. Looking ahead ...